Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Pepsi's slump is mainly due to aggressive price hikes and high T-bond yields, not diworsification or health trends.

Zoom shows strong profitability and cash flow despite modest growth and cautious guidance, weighed by SBC and macro risks.

YieldMax has garnered a reputation for offering intriguing, innovative exchange traded funds (ETFs) with an emphasis on high ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

Shares of Huntington Ingalls Industries have rallied at the start of 2025 as the Trump administration aims to revitalize U.S.

Wall Street is overwhelmingly optimistic where Nvidia is concerned. Among the 69 analysts who follow the company, 87% have a ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down ...

These three TFSA investments are some of the best options out there, especially while each remain on sale. The post How I’d ...